Ispire Technology Inc. develops, commercializes, sells and distributes branded e-cigarettes and cannabis vaping products. Its e-cigarette products are marketed under the Aspire name through a global distribution network, while cannabis vaping hardware is sold under the Ispire brand, primarily through original design manufacture relationships with other cannabis vapor companies.
Recurring ISPR news includes quarterly financial results, cash and working-capital updates, product and customer activity, manufacturing and distribution developments, and regulatory technology initiatives for electronic nicotine delivery systems. Coverage also includes IKE Tech, a joint venture involving Ispire, and its age-gating, authentication and point-of-use compliance technology tied to FDA discussions, PMTA submissions and flavored ENDS regulation.
IKE Tech (NYSE:ISPR) welcomed the FDA's March 2026 draft guidance that, for the first time, explicitly recognizes continuous, device-level age verification (Device Access Restrictions) as a factor in PMTA APPH determinations.
IKE Tech highlights its April 2025 component PMTA, a validated BLE/biometric/blockchain age-gating system with a multi-center human factors study showing 100% successful verification (n=101) and 0% underage activation.
Ispire (NASDAQ: ISPR) says FDA draft guidance on flavored ENDS recognizes device-level age verification and may unlock a $50 billion U.S. total addressable market by enabling lawful transition of primarily illicit flavored vape sales into a compliant ecosystem. Ispire's 40% JV, IKE Tech, claims $5M–$20M annual SaaS revenue per customer and says it filed the first component PMTA for continuous, blockchain-enabled age-gating technology with human-factors results cited as 100% underage prevention and 100% demographic accuracy.
Ispire Technology (NASDAQ: ISPR) will participate in the 38th Annual ROTH Conference in Dana Point, California from March 22-24, 2026. Management will host a fireside chat on March 23, 2026 at 8:00 a.m. PT in Blue-Consumer-Salon 2.
Investors may request one-on-one meetings by contacting a ROTH representative or emailing Ispire@KCSA.com.
Ispire Technology (NASDAQ: ISPR) reported fiscal Q2 2026 results for the quarter ended December 31, 2025, showing revenue of $20.3M (versus $41.8M prior year) and a net loss of $6.6M ($0.12 per share). Cash totaled $17.6M and working capital was $3.5M.
The company said gross profit was $3.5M (17.1% margin) and operating expenses declined to $10.3M as AR fell 19.5% to $37.9M, reflecting a shift to higher-quality customers and cost controls.
Ispire (NASDAQ: ISPR) said IKE Tech, a joint venture with Ispire as a founding partner, was invited to an FDA Roundtable on PMTA submissions on February 10, 2026. The invitation, limited to 30 companies, recognizes IKE Tech as a stakeholder and the role of point-of-use age-gating technology. IKE will join the Manufacturing Controls panel and has submitted the first-ever component PMTA for an interoperable, blockchain-enabled Bluetooth age-verification system.
The company framed the engagement as a chance to inform PMTA guidance and advance regulatory-ready, youth-protective technical controls for ENDS products.
WM Technology (Nasdaq: MAPS) appointed Harry DeMott and Brent Cox to its Board of Directors effective February 1, 2026, and confirmed Susan Echard will transition from a contracted CFO role to full employment effective January 30, 2026. The additions emphasize cannabis industry, technology, and capital markets experience.
The company said the new directors bring board and operating experience to support Weedmaps marketplace and the firm's growth in the evolving cannabis sector.
Ispire Technology (NASDAQ: ISPR) will hold its fiscal second quarter 2026 earnings conference call at 8:00 am ET on Friday, February 6, 2026 to discuss results for the quarter ended December 31, 2025. The call is available by dial-in or live webcast.
Dial-in numbers include US 877-451-6152 and International +1 201-389-0879. The webcast link is provided for registration; attendees should access it at least fifteen minutes early. A playback replay will be available through 11:59 pm ET on February 20, 2026 with passcode 13758138.
Ispire Technology (NASDAQ: ISPR) will unveil a fully reengineered cannabis hardware ecosystem at MJBizCon 2025, Dec 2–5 at the Las Vegas Convention Center. The launch introduces three product families—E-Series (Essentials), S-Series (Specialized) and C-Series (Custom/ODM)—with devices designed for varied oil viscosities, activation types (draw/button/dual) and global compliance. Key models include compact draw-activated and high-viscosity units, flagship dual-activation devices, and fully custom ODM options. Senior executives, including VP of Sales John Monds, will be available for on-site meetings; scheduling via john.monds@getispire.com.
Ispire Technology (NASDAQ: ISPR) and IKE Tech responded to the U.S. Food and Drug Administration's new enforcement direction under the Nov. 17, 2025 continuing resolution that requires the FDA to allocate at least $200 million of its $712 million in user fees to ENDS enforcement and to fund a multi-agency task force with $2 million for removing illegal imports.
Both companies promoted their blockchain-enabled, FDA-submitted System-on-a-Chip and age-verification solutions as technology to enable real-time product tracing, device-level identity validation, and interoperability to curb illicit disposable vapes and protect youth in the $30 billion flavored vape market.
Viasat (NASDAQ: VSAT) was selected by the U.S. Government under a sole‑source, multi‑million dollar IDIQ award to develop a next‑generation, high‑assurance, high‑speed Ethernet Data Encryptor (EDE) for classified cloud data centers and transport networks.
Key technical claims include 16× more bandwidth, an estimated 60% power savings, and an advertised encryption density of 3.2 Tbps aggregate per standard rack unit (enough for >100,000 simultaneous 4K streams). The product will build on Viasat’s KG‑142 heritage and use its PSIAM™ reprogrammable architecture for software‑based upgrades.